The protein tyrosine phosphatases (PTPs) PTP-SL, STEP and HePTP are mitogen-activated protein kinase (MAPK) substrates and regulators that bind to MAPKs through a kinase-interaction motif (KIM) located in their non-catalytic regulatory domains. We have found that the binding of these PTPs to the MAPKs extracellular-signal-regulated kinase 1 and 2 (ERK1/2), and p38α is differentially determined by the KIM-adjacent Cterminal regions of the PTPs, which have been termed kinasespecificity sequences, and is influenced by reducing agents. Under control conditions, PTP-SL bound preferentially to ERK1/2, whereas STEP and HePTP bound preferentially to p38α. Under reducing conditions, the association of p38α with STEP or HePTP was impaired, whereas the association with PTP-SL was unaffected. On the other hand, the association of ERK1/2 with HePTP was increased under reducing conditions, whereas the association with STEP or PTP-SL was unaffected. In intact cells, PTP-SL and STEP distinctively regulated the kinase activity and the nuclear translocation of ERK1/2 and p38α. Our results suggest that intracellular redox conditions could modulate the activity and subcellular location of ERK1/2 and p38α by controlling their association with their regulatory PTPs.
INTRODUCTION
In mammalian cells, three major mitogen-activated protein kinase (MAPK) subfamilies have been characterized, which are regulated by distinct extracellular signals and show differential substrate specificities; these include the extracellular-signalregulated kinases (ERK1/2), the c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases and the p38 MAPKs. Overall, JNK and p38 MAPKs account for the cell response to stress and inflammation conditions, whereas ERK1/2 are mainly activated by growth and differentiation factors (reviewed in [1] [2] [3] ). Additional MAPK family members include the ERK3, ERK5/big MAPK 1 (BMK1), ERK7 and ERK8 MAPKs [4] [5] [6] [7] [8] . An important factor in the definition of the signal specificity within each MAPK signalling pathway is the assembly of their components into dynamic multimolecular complexes, that bring together the distinct effectors and regulators of each pathway, in a tightly regulated manner and within specific subcellular compartments. Components of MAPK pathways include the MAPKs themselves, activating MAPK kinases, inactivating phosphatases, MAPK substrates, and regulatory and scaffolding MAPK modulators [1] [2] [3] [9] [10] [11] [12] [13] . The association of substrates and effectors with the MAPKs is facilitated by the existence of a docking groove on the kinases, where the individual interaction sites of those Abbreviations used: BMK1, big MAPK1; DTT, 1,4-dithiothreitol; ERK, extracellular-signal-regulated kinase; EGF, epidermal growth factor; GST, glutathione S-transferase; HA, haemagglutinin; HePTP, haemopoietic PTP; JNK, c-Jun N-terminal kinase; KIM, kinase-interaction motif; KIS, kinase-specificity sequence; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; 2-ME, 2-mercaptoethanol; MKP, MAPK phosphatase; NMDA, N-methyl-D-aspartate; PKA, cAMP-dependent protein kinase; PTP, protein tyrosine phosphatase; PTP-SL, STEP-like PTP; STEP, striatal-enriched phosphatase. 1 Present address: Grupo de Desarrollo de Ensayos, Departamento de Terapias Experimentales, Centro Nacional de Investigaciones Oncológicas (CNIO), C/ Melchor Fernández Almagro, 3, 28029 Madrid, Spain. 2 To whom correspondence should be addressed (e-mail rpulido@ochoa.fib.es).
molecules recognize their binding sites [14] [15] [16] . Several classes of interaction sites for MAPKs have been defined, which are present in a wide array of MAPK-interacting molecules. These interaction sites include an arginine-and leucine-rich motif [δ domain, D box, kinase-interaction motif (KIM)], as well as a phenylalanine-rich motif (Phe-Xaa-Phe-Pro motif), which are present either alone or in combination in the different MAPK effectors and substrates and confer specificity to recognize the distinct MAPKs [14, [17] [18] [19] . ERK1/2 associate with PTP-SL [striatal-enriched phosphatase (STEP)-like protein tyrosine phosphatase (PTP)] through the KIM, located in the regulatory non-catalytic domain of the phosphatase; this association leads to phosphorylation/dephosphorylation events between these two enzymes, which have a regulatory role in the signalling through the MAPK pathways [18, 20] . Additional MAPK family members that associate physically and functionally with PTP-SL include p38α and ERK5/BMK1 [18, 21] . The PTP-SL-related tyrosine phosphatases STEP and HePTP [haematopoietic PTP; also named leucocyte (LC)-PTP] contain a conserved KIM sequence outside of their catalytic domains and are also substrates of MAPKs [20] [21] [22] [23] . PTP-SL and STEP are mainly expressed in specialized brain areas [24] [25] [26] [27] [28] [29] , whereas HePTP is expressed in leucocytes [30] [31] [32] . HePTP has been found to suppress the T-cell-antigen-receptormediated activation of MAPKs upon KIM-mediated binding to these enzymes [22, 33, 34] . Interestingly, the binding of both PTP-SL and HePTP to the MAPKs ERK1/2 and p38α is regulated by the phosphorylation of their KIMs by the cAMP-dependent protein kinase, PKA, which has consequences for the activation of these kinases and their translocation to the nucleus [35, 36] . In addition, the activity of STEP has also been reported to be down-regulated by PKA after neuronal cell activation through dopamine receptors [37] . In the present paper, we report the comparative study of the physical and functional association of PTP-SL, STEP and HePTP with the ERK1/2 and p38α MAPKs. We provide evidence that PTP-SL, STEP and HePTP associate differentially with ERK1/2 and p38α, in a process determined by the KIM-adjacent C-terminal regions of these PTPs, and are influenced by the reducing conditions. Furthermore, PTP-SL and STEP have been found to distinctively regulate the activity and the nuclear translocation of ERK1/2 and p38α.
MATERIALS AND METHODS

Plasmid constructions, mutagenesis, chimaeras and purification of glutathione S-transferase (GST) fusion proteins
The PTP-SL, STEP, HePTP, ERK2 and p38α cDNA constructs and primary and secondary antibodies used in this study have been previously described in [18, 20, 35] . Rabbit polyclonal anti-STEP 1-369 and anti-STEP 1-107 antibodies were obtained by immunization of rabbits with GST-STEP 1-369 or GST-STEP 1-107 respectively. Some cross-reactivity towards PTP-SL was observed with the anti-STEP 1-369 polyclonal serum. Monoclonal anti-GST antibody was obtained in our laboratory. pRK5-GST-PTP-SL 147-549 and pRK5-GST-STEP 1-369 mammalian expression vectors were constructed by PCR with a primer containing a Kozak sequence followed by a start codon and the Schistosoma japonicum GST sequence. All point mutations were performed by PCR oligonucleotide site-directed mutagenesis, and mutations were confirmed by DNA sequencing. The chimaera PTP-SL-KIM-STEP [PTP-SL(147-239)-STEP(58-107)] was constructed by PCR using oligonucleotides that were complementary to the regions Nterminal to the KIM of PTP-SL and C-terminal to the KIM of STEP. The chimaera STEP-KIM-PTP-SL [STEP(1-57)-PTP-SL(240-288)] was constructed by PCR using oligonucleotides that were complementary to the regions N-terminal to the KIM of STEP and C-terminal to the KIM of PTP-SL. The chimaeras STEP-PTP-SL [STEP(1-107)-PTP-SL(289-549)] and PTP-SL-STEP [PTP-SL(147-288)-STEP(108-369)] were made using an in frame internal EcoRI restriction site located at amino acids 288 of PTP-SL and 107 of STEP. Amino acid numbering of PTP-SL, STEP and HePTP is according to [26] , [24] and [31] respectively. Glutathione-Sepharose purification of the GST fusion proteins was performed by standard procedures.
Cell culture, transfection and cell lysis
Human embryonic kidney HEK-293, simian kidney COS-7 and rat fibroblast Rat-1 cell lines were grown in Dulbecco's minimal essential medium containing high glucose (4.5 g/l) supplemented with 5 % (COS-7 cells) or 10 % (HEK-293 and Rat-1 cells) heatinactivated foetal calf serum. The cells were transfected using the DEAE-dextran method (COS-7 cells) or the calcium phosphate precipitation method (HEK-293 cells) and were harvested 48 h post-transfection. Haemagglutinin (HA)-ERK2 or HA-p38α from transfected COS-7 cells were activated by cell treatment with 50 ng/ml epidermal growth factor (EGF; Invitrogen) for 5 min or 0.5 M sorbitol (Sigma) for 30 min respectively. For association experiments under standard conditions (see Figures 1-4 Figure 7 ), cells were lysed in lysis buffer A alone (control conditions) or in lysis buffer A plus 2 mM 1,4-dithiothreitol (DTT; Roche) or 10 mM 2-mercaptoethanol (2-ME; Merck).
Precipitation with GST fusion proteins, immunoprecipitation, immunoblotting, immunofluorescence and in vitro kinase assays For precipitation, cell lysates were incubated with 2 µg of the distinct fusion proteins, or with 30 µl of glutathione-Sepharose in the case of HEK-293 cells transfected with pRK5-GST-PTP-SL 147-549 or pRK5-GST-STEP 1-369. The samples were washed with 20 mM Hepes, pH 7.5, 150 mM NaCl, 10 mM Na 4 P 2 O 7 , 0.1 % (v/v) Igepal CA-630 and 10 % (v/v) glycerol. Immunoprecipitation, immunoblotting, and immunofluorescence were performed as described in [18, 20] . For in vitro kinase assays, cells were lysed in lysis buffer A (see above), and the immunecomplex pellets containing EGF-activated HA-ERK2 or sorbitolactivated HA-p38α were incubated at room temperature (20 • C) for 20 min with constant shaking in kinase reaction buffer (20 mM Hepes, pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 2 mM Na 3 VO 4 and 0.3 µM ATP), in the presence of 2 µg of myelin basic protein (MBP) and 2 µCi of [γ - 32 P]ATP per sample. The reactions were stopped by adding SDS sample buffer and boiling, followed by SDS/PAGE (15 % gels) under reducing conditions. Gels were processed for quantification of the incorporated radioactivity into the MBP substrate proteins as described in [16] .
RESULTS
PTP-SL, STEP and HePTP differentially associate with ERK1/2 and p38α through their N-terminal regulatory domains
PTP-SL, STEP and HePTP tyrosine phosphatases have in common the existence of a highly conserved KIM. Upon binding through the KIM, the MAPKs ERK1/2 phosphorylate PTP-SL, whereas PTP-SL dephosphorylates and inactivates ERK1/2 [20] . To investigate in parallel the association of PTP-SL, STEP and HePTP with ERK1/2 and p38α, Rat-1 cell lysates were precipitated with GST-PTP-SL, GST-STEP or GST-HePTP fusion proteins purified from Escherichia coli, followed by immunoblot with anti-ERK1/2 or anti-p38α antibodies. GST-PTP-SL 147-288, GST-STEP 1-107 and GST-HePTP 1-79 fusion proteins, containing the MAPK binding domains ( Figure 1A ), associated with ERK1/2 and p38α ( Figure 1B , lanes 2, 4 and 6). The mutational analysis of the KIM on PTP-SL has shown that either of the two arginine residues within the KIM (Arg 228 and Arg 229 ) is essential for ERK1/2 binding [18] . Accordingly, amino-acid substitution of the equivalent residues on the KIM of STEP or HePTP [mutants Arg 46 →Ala (R46A)/R47A and R20A/R21A respectively] impaired the association with ERK1/2 and p38α ( Figure 1B , lanes 3, 5 and 7). Also, the GST-PTP-SL 289-549 and GST-STEP 108-369 fusion proteins, lacking the MAPK-binding domain of these PTPs, did not associate with ERK1/2 or p38α ( Figure 1B , lanes 10 and 12). Interestingly, GST-PTP-SL 147-288 associated more strongly with ERK1/2 than with p38α, whereas GST-STEP 1-107 and GST-HePTP 1-79 associated more strongly with p38α than with ERK1/2 ( Figure 1B ). Similar patterns of association were found (A) Schematic representation of the structure of the PTP-SL, STEP and HePTP proteins used; amino acid numbering is according to [24] , [26] and [31] respectively. (B) Equal amounts of Rat-1 cell lysates were precipitated with 2 µg of the different GST fusion proteins (purified from E. coli) and glutathione-Sepharose, as indicated. Samples were resolved by 10 % SDS/PAGE under reducing conditions, followed by immunoblot analysis with anti-ERK1/2 (upper panels) or anti-p38α (lower panels) antibodies. (C) HEK-293 cells were transfected with pRK5-GST (lanes 2), or with pRK5-GST-PTP-SL or pRK5-GST-STEP wild-type or mutants, as indicated, in order to express the fusion proteins ectopically. After 48 h, the GST fusion proteins were precipitated from equal amounts of cell lysates with glutathione-Sepharose, and the co-precipitated endogenous MAPKs were detected by immunoblot analysis with anti-ERK1/2 (upper panel) or anti-p38α (middle panel) antibodies. In lane 1, upper and middle panels, 50 µg of total lysates were loaded. In the lower panel, 50 µg of total lysates were loaded, and analysed by immunoblot with an anti-GST antibody. Experiments were performed at least three times with similar results, and a representative experiment is shown.
upon activation of MAPKs by cell treatment with EGF or sorbitol (results not shown). To corroborate the differential association of PTP-SL and STEP with ERK1/2 and p38α, experiments were performed using GST fusion proteins overexpressed in mammalian cells. GST-PTP-SL 147-549 or GST-STEP 1-369 (that span the complete cytosolic portion of these PTPs; Figure 1A ) were ectopically expressed in HEK-293 cells; after transfection and cell lysis, the fusion proteins were precipitated with glutathione-Sepharose and the co-precipitated MAPKs were visualized by immunoblotting ( Figure 1C ). As shown, GST-PTP-SL preferentially co-precipitated ERK1/2, whereas GST-STEP preferentially co-precipitated p38α.
Chimaeric proteins were designed containing the N-terminal MAPK-binding domain of STEP followed by the PTP domain of PTP-SL (STEP-PTP-SL chimaera), or vice versa (PTP-SL-STEP chimaera; Figure 2A ), and their association with the MAPKs was assessed as above. The GST-STEP-PTP-SL chimaeric protein associated with ERK1/2 and p38α in a manner equivalent to that of the STEP wild-type protein ( Figure 2B, lanes 4 and 5) , whereas the GST-PTP-SL-STEP chimaera associated with these MAPKs in the same way as PTP-SL wild-type ( Figure 2B , lanes 3 and 6). Taken together, these results indicate that ERK1/2 and p38α differentially associate with the N-terminal regulatory domains of PTP-SL, STEP and HePTP.
Regions outside the KIM contribute to the differential association of PTP-SL, STEP and HePTP with ERK1/2 and p38α
To test whether the differences in the core KIM amino-acid sequences of PTP-SL and HePTP ( Figure 3A ) could account for their differential recognition by the MAPKs, amino-acidsubstitution mutants were generated that exchanged the core KIM sequences of these two PTPs (mutants PTP-SL T236M and S234A/T236M; and mutants HePTP M28T and A26S/M28T), and their association with ERK1/2 or p38α was analysed using GST fusion proteins and Rat-1 cell lysates, as above. GST-PTP-SL 147-288 T236M or S234A/T236M mutants associated slightly poorer with both ERK1/2 and p38α than GST-PTP-SL 147-288 wild-type did ( Figure 3B, lanes 3-5) , whereas GSTHePTP 1-79 M28T or A26S/M28T mutants associated with both ERK1/2 and p38α almost in the same manner as GSTHePTP 1-79 wild-type ( Figure 3B, lanes 6-8) . Thus these KIM mutations did not revert the differential association of GST-PTP-SL and GST-HePTP with ERK1/2 and p38α, but rather slightly diminished or augmented the association of both MAPKs observed with the wild-type PTPs. Next, chimaeric proteins were obtained by swapping the regions adjacent to the KIM in PTP-SL and STEP ( Figure 4A ), and their association with ERK1/2 and p38α was also analysed. Remarkably, the pattern of association of the chimaera containing the STEP region C-terminal to the KIM (PTP-SL-KIM-STEP) was similar to that shown by wildtype STEP: association with p38α > association with ERK1/2 ( Figure 4B, lanes 4 and 6) . Conversely, the chimaera containing the PTP-SL region C-terminal to the KIM (STEP-KIM-PTP-SL) associated with the MAPKs in a similar manner to wild-type PTP-SL: association with ERK1/2 > association with p38α ( Figure 4B,  lanes 3 and 5) . These findings indicate that molecular determinants outside the KIM exist that are important for the differential association of PTP-SL and STEP, and probably HePTP with ERK1/2 and p38α, and suggest that the non-catalytic amino-acid regions C-terminal to the KIM on PTP-SL and STEP regulate their selective binding to these MAPKs. We have termed these regions as kinase-specificity sequences (KISs).
Differential effects of PTP-SL and STEP on the function and nuclear translocation of ERK2 and p38α
To test the effect of PTP-SL and STEP on the catalytic activity of ERK2 and p38α in intact cells, COS-7 cells overexpressing the PTPs and the MAPKs were activated with EGF (for HA-ERK2-transfected cells) or osmotic shock (for HA-p38α-transfected cells), followed by immunoprecipitation with the anti-HA 12CA5 monoclonal antibody and in vitro kinase assays. As observed, HA-ERK2 and HA-p38α catalytic activities were decreased in cells co-expressing PTP-SL 147-549; however, the catalytic activity of HA-ERK2 was only slightly decreased, and that of HA-p38α was not modified upon co-expression with STEP 1-369 ( Figure 5 ). It should be mentioned that the absence of inhibition of MAPK catalytic activities in these experiments was not due to the lack of catalytic activity on the STEP molecules used in our studies, as monitored by in vitro p-nitrophenyl phosphate dephosphorylation assays following immunoprecipitation of this PTP (results not shown). The effects of the PTP-SL-STEP and STEP-PTP-SL chimaeras on the catalytic activity of MAPKs in intact cells was also tested. As shown, the PTP-SL-STEP chimaera (containing the MAPK-binding domain of PTP-SL and the catalytic domain of STEP, as depicted in Figure 2 ) inactivated HA-ERK2 and HA-p38α to a similar extent as that by PTP-SL, whereas the catalytic inactivation of these MAPKs by the STEP-PTP-SL chimaera (containing the MAPK-binding domain of STEP and the catalytic domain of PTP-SL) was weaker ( Figure 5C ). These results indicate that the MAPK-binding domain of PTP-SL and STEP has an important role in the differential regulation of the catalytic activities of ERK1/2 and p38α by these two PTPs, and suggest the existence of specific mechanisms that control the regulatory effects of PTP-SL and STEP on MAPKs in intact cells.
Since no correlation was observed between the association of STEP with MAPKs, as monitored in the pull-down and coprecipitation assays using GST-STEP fusion proteins, and the catalytic inactivation of MAPKs by STEP, the in vivo physical association of STEP with ERK1/2 and p38α was assessed in transfected COS-7 cells by double immunofluorescence analysis, and compared with that observed for PTP-SL. Overexpression of PTP-SL 147-549 retained HA-ERK2 and HA-p38α in the cytoplasm ( [35] and Figure 6 ). However, overexpression of STEP 1-369 resulted in a weak or no cytoplasmic retention of HA-ERK2 or HA-p38α respectively (Figure 6 ), and did not block the nuclear accumulation of these MAPKs, in correlation with the poor inhibition of their activity by this PTP. Finally, colocalization experiments were performed on COS-7 cells using the STEP-PTP-SL and PTP-SL-STEP chimaeric proteins. As shown, the PTP-SL-STEP chimaera retained HA-ERK2 and HA-p38α in the cytoplasm, as did PTP-SL, whereas the STEP-PTP-SL chimaera did not retain these MAPKs efficiently, unlike STEP ( Figure 6 ). Thus PTP-SL associates in the cytoplasm of intact COS-7 cells with ERK1/2 and p38α, and effectively blocks their activation and entry into the nucleus; however, the co-expression of STEP and these MAPKs in COS-7 cells did not result in their physical association, and no inhibition of MAPK catalytic activity and nuclear translocation was observed.
Reducing conditions influence the association of PTP-SL, STEP and HePTP with MAPKs
To find an explanation for the differences observed in the association of STEP with MAPKs in cell lysates and in intact cells, comparative pull-down assays with GST-STEP 1-107 and GST-PTP-SL 147-288 (lacking the PTP catalytic domains; see Figure 1A ) were performed using different conditions of cell lysis, including the presence or absence of reducing agents. As illustrated in Figure 7 , the association of GST-STEP with p38α was lost when the assay was performed in the presence of reducing agents, such as DTT or 2-ME ( Figure 7A , lower panel, lane 7; Figure 7B, lower panel, lanes 2 and 3) . This effect was specific, since the association of GST-STEP with ERK1/2 ( Figure 7A , upper panel, lane 7), or of GST-PTP-SL with p38α or ERK1/2 ( Figure 7A , lane 3) was not significantly affected by the presence of reducing agents. Furthermore, the binding to p38α of the chimaera containing the KIS of STEP (PTP-SL-KIM-STEP, as depicted in Figure 4A ) was also lost upon reducing conditions ( Figure 7A , lower panel, lane 8). To rule out the possibility that GST could be involved in the inhibition of the interaction of STEP with p38α upon reducing conditions in the above experiments, co-precipitation experiments were performed using STEP 1-369 and HA-p38α overexpressed in COS-7 cells ( Figure 7C ). As observed, STEP 1-369 was co-precipitated with HA-p38α under control conditions ( Figure 7C , lane 2), but not in the presence of the reducing agent DTT ( Figure 7C, lane 3) . Finally, the association of GST-HePTP 1-79 with MAPKs was also assessed COS-7 cells were co-transfected with pCDNA3-HA-ERK2 or pECE-HA-p38α plus pRK5 vector alone (mock), or plus pRK5-PTP-SL or pRK5-STEP wild-type or chimaeric proteins (as in Figure 5 ), as indicated. After 48 h, cells were co-stained and analysed by immunofluorescence. HA-ERK2 and HA-p38α were stained with the mouse anti-HA monoclonal antibody 12CA5 plus rhodamine-conjugated goat anti-mouse antibody. PTP-SL, or the chimaeras PTP-SL-STEP or STEP-PTP-SL were stained with the rabbit polyclonal anti-PTP-SL antibody, and STEP was stained with the rabbit polyclonal anti-STEP 1-107 antibody. In both cases, FITC-conjugated goat anti-rabbit was used as a secondary antibody. HA-ERK2 or HA-p38α nuclear localization is scored as the percentage of cells co-expressing the PTPs and HA-ERK2 or HA-p38α that showed the MAPK located into the nucleus. Results are means + − S.D. of at least two separate experiments, with at least 50 double positive cells scored for each bar.
Table 1 Summary of the association of PTP-SL, STEP and HePTP with ERK1/2 and p38α
Estimated association based on pull-down assays, relative to the association of ERK1/2 with PTP-SL under our control experimental conditions: +++, strong association; + , moderate association; − / + , weak association. in the presence of reducing agents. Interestingly, a distinct pattern of MAPK association, in comparison with GST-STEP and GST-PTP-SL, was found for GST-HePTP under reducing conditions: the association with ERK1/2 was increased, whereas the association with p38α was decreased ( Figure 7D, lane 2) . These results are summarized in Table 1 . Thus reducing conditions differentially influence the association of PTP-SL, STEP and HePTP with the MAPKs ERK1/2 and p38α, independently of the catalytic domains of the PTPs.
DISCUSSION
Selective recognition of substrates and effectors by MAPKs involves electrostatic and hydrophobic interactions between key residues at the MAPK docking grooves and at the interaction sites of the substrates and effectors. These interactions are thought to provide selectivity for both the differential regulation and signalling outputs of the distinct MAPK pathways upon activation.
The tyrosine phosphatases PTP-SL, STEP and HePTP are ERK1/2 and p38α substrates and regulators that possess a conserved interaction site, the KIM, for these MAPKs in their N-terminal regulatory domains [18, 20] . In the present study, the regulation of the physical and functional association of PTP-SL, STEP and HePTP with ERK1/2 and p38α has been analysed comparatively. Using GST pull-down and co-precipitation assays, PTP-SL has been found to bind ERK1/2 more efficiently than p38α, whereas STEP and HePTP bind p38α more efficiently than ERK1/2. In addition, we have identified a region adjacent to the KIM of these three PTPs, the KIS (see Figures 4 and 8 ) that is involved in their differential recognition of ERK1/2 and p38α, as well as in the distinctive effects of reducing agents in their binding capabilities to these MAPKs (summarized in Table 1 ). The present study and previous studies [18, 34] have shown that mutation of the arginine residues within the KIM of PTP-SL, STEP or HePTP abrogate binding to ERK1/2 and p38α, indicating that these motifs are the major molecular determinants on the PTPs that are responsible for binding to MAPKs. However, binding specificity is only achieved in the context of an appropriate KIS, C-terminal to the KIM, which discriminates between ERK1/2 and p38α to differentially target them to PTP-SL, STEP, or HePTP. Thus the combination of a highly conserved KIM with a variable KIS (see Figure 8 ) allows tight and differential binding of these PTPs to their cognate MAPKs. In this regard, different subregions in the MAPK binding domains of other MAPK effectors or substrates, including MAPK phosphatases (MKPs) and ETS transcription factors, have also been shown to be involved in the differential binding to MAPKs [38, 39] . In addition, the association of distinct MAPKs with the different MKPs, as well as with their activating MAPK kinases, has been found to be controlled by specificity mechanisms that involve several parts of these molecules [40] [41] [42] [43] . Our results indicate that the differential recognition of MAPKs by PTP-SL, STEP and HePTP involves different regions of their N-terminal MAPK-binding domains, and that the PTP catalytic domains are dispensable for such recognition. The catalytic domain of PTP-SL has been crystallized, together with a partial fragment (helix α0) of the KIS of this PTP; interestingly, extensive intra-molecular interactions are predicted that stabilize the helix α0 of PTP-SL, which is proposed to play a role in the orientation of the phosphatase in a favourable position for interaction with ERK2, underscoring the importance of this region in the regulation of PTP-SL function [44] . In addition, an interaction between the catalytic domain of PTP-SL and ERK2 is expected to exist under physiological conditions to facilitate the dephosphorylation and inactivation of the kinase [44] . In this regard, the inactivation of MAPKs in COS-7 cells by the PTP-SL-STEP and the STEP-PTP-SL chimaeras was partially influenced by their respective PTP domains ( Figure 5 ). In spite of their identical KIMs and their relatively well conserved KISs (Figure 8 and [45] ), the binding patterns of PTP-SL and STEP to ERK1/2 and p38α are different; on the other hand, although STEP and HePTP amino-acid sequences within this region show less conservation, their binding patterns to ERK1/2 and p38α, under control conditions, are similar (Table 1) . HePTP is predominantly expressed in leucocytes, where it targets MAPKs and regulates T-cell-antigen-receptor signalling [22, 33, 34, 46] . Interestingly, we show opposite effects of reducing agents in the modulation of the association of HePTP with ERK1/2 and p38α, suggesting that redox conditions could act in leucocytes as a switch to control the interaction of HePTP with each of these MAPKs. Also, these findings could explain some controversial results regarding the specificity of HePTP towards p38α [22, 23, 46] . The expression of PTP-SL and STEP isoforms is developmentally regulated in the brain [25] [26] [27] [28] [29] , making possible a specialization in the control of ERK1/2 and p38α functions by these two PTPs in particular brain areas. In vitro, STEP binds ), and lysates were precipitated with 2 µg of GST-HePTP and processed for immunoblot as in (A). In (B), distinct input of cell lysates was used to obtain detectable bands in the control points, making the relative signals of the GST fusion protein with the distinct MAPKs non-comparable. In all cases, when comparing control with the different redox conditions, equal amounts of cell lysates were used. Experiments were performed at least three times with similar results, and a representative experiment is shown. Conserved residues are shadowed. Amino acids are indicated using the one-letter code.
very efficiently to p38α under control conditions; however, we have been unable to detect co-localization of these two molecules, or inactivation of p38α by STEP, in intact cells. Our results on the inhibitory effect of reducing conditions on the association of STEP with p38α provides an explanation for this apparent discrepancy. Additional mechanisms may exist that account for the regulation of the binding and the activity of STEP towards MAPKs. For instance, PKA is expected to regulate in vivo the functions of STEP by phosphorylation of the KIM in a specific manner [35, 37] . Furthermore, different putative phosphorylation sites are present on the KIS of STEP, including the MAPK phosphorylation sites, raising the possibility that phosphorylation of this region could regulate in vivo the specificity of the association between STEP and the MAPKs. Our findings that the differential association of STEP with ERK1/2 and p38α is observed using both bacterial-and mammalian-overexpressed recombinant STEP proteins, suggest that this phenomenon is independent of STEP phosphorylation. However, the possibility exists that a protein phosphatase, not inactivated under our celllysis conditions, could dephosphorylate STEP in the COS-7 cell lysates. In addition, an effect of the reducing conditions on the binding properties of p38α towards STEP cannot be excluded. Furthermore, STEP has been found to suffer a calcium-dependent proteolytic cleavage, whose functional consequences are not yet known [47] , and a distinctive pattern of STEP isoforms exist in comparison with PTP-SL or HePTP [48] . Finally, the association of STEP with N-methyl-D-aspartate (NMDA) receptor complexes and with the Src family kinase, Fyn, has been reported, and a role for STEP in the regulation of NMDA-receptor-channel activity in neurons has been demonstrated [49, 50] ; the possibility exists that the functional regulation of the NMDA receptor by STEP is linked to the regulated association of this PTP with kinases in neurons, including Fyn and/or MAPKs. Further work will be necessary to elucidate how reducing conditions, or other regulatory mechanisms, may affect the functional properties of STEP in neurons.
